Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Reuters4d
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether it will ...
CNN on MSN10d
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...